Utilizing intestinal ultrasound to assess treatment response in ulcerative colitis [0.03%]
利用肠道超声评估溃疡性结肠炎的治疗反应
Shintaro Sagami,Taku Kobayashi
Shintaro Sagami
Intestinal ultrasound (IUS) enables frequent, noninvasive assessment of inflammatory activity in ulcerative colitis and can support treat-to-target decisions without bowel preparation. Evidence from prospective cohorts indicates that early ...
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunity-findings from the UAE Epi-IBD study [0.03%]
炎症性肠病的快速诊断和治疗减轻：利用机会窗口的研究发现（来自阿联酋Epi-IBD研究）
Thaer Khaleel Swaid,Layth Raafat Hamzeh,Laurette L Bukasa et al.
Thaer Khaleel Swaid et al.
Background/aims: To determine time to diagnosis (TTD) and its impact on surgery and advanced therapy (AT) burden in inflammatory bowel disease (IBD) in a multi-ethnic United Arab Emirates (UAE) cohort, a region in the acc...
Transabdominal intestinal ultrasound parameters as intermediate treatment targets in a treat-to-target strategy for moderate-to-severe ulcerative colitis [0.03%]
肠超声作为中重度溃疡性结肠炎治疗方案中治疗目标的可行性研究
Longxi Yun,Zhaojue Wang,Qingli Zhu et al.
Longxi Yun et al.
Background/aims: This study aimed to investigate the prognostic value of early post-induction intestinal ultrasound (IUS) findings in predicting long-term clinical outcomes among patients with moderate-to-severe ulcerativ...
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease [0.03%]
对炎症性肠病先进综合疗法的现实世界应用及认知的感知
Hsin-Yun Wu,Zhi-Che Chen,Meng-Tzu Weng et al.
Hsin-Yun Wu et al.
Background/aims: Combining therapies targeting distinct pathways shows promise in breaking the therapeutic ceiling for inflammatory bowel disease. The study explored real-world experiences and gaps between current evidenc...
Comments on "Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study" [0.03%]
关于“影响溃疡性结肠炎患者坚持使用维多珠单抗治疗一年的因素：一项多中心回顾性真实世界研究”的评论
Joaquín Borrás-Blasco,Alejandro Valcuende-Rosique,Silvia Cornejo-Uixeda
Joaquín Borrás-Blasco
Tofacitinib in older patients with ulcerative colitis: balancing efficacy and safety [0.03%]
托法替尼治疗溃疡性结肠炎老年患者：疗效和安全性评估
Yoon Suk Jung
Yoon Suk Jung
Dyslipidemia and hyperglycemia synergistically increase the risk of intestinal barrier dysfunction: evidence from a case-control study in China [0.03%]
中国病例对照研究证据表明血脂异常与高血糖协同增加肠屏障功能障碍风险
Chao Zhang,Dandan Lin,He Yu et al.
Chao Zhang et al.
Background/aims: Previous evidence regarding the combined effects of metabolic disorders on intestinal barrier function (IBF) remains limited. We hypothesized that metabolic disorders interact to increase the risk of inte...
Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease [0.03%]
janus激酶抑制剂与炎症性肠病患者生物制剂治疗的安全性比较
Gursimran S Kochhar,Himsikhar Khataniar,Parambir S Dulai et al.
Gursimran S Kochhar et al.
Background/aims: There is a paucity of data regarding the comparative safety of Janus kinase inhibitors (JAKi) compared to biologic therapy in inflammatory bowel disease (IBD). ...